


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Substitute for form 1449PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **3****Complete if Known**

Application Number	10/767,870
Filing Date	01/29/2004
First Named Inventor	Mark Puder
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	701039-53543

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
<i>AS</i>	AA	US-5,760,068	06/02/1998	Talley et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
<i>AS</i>	BA	WO 00/32189	06/08/2000	GAO, D. et al.		

Examiner
SignatureDate
Considered

9/17/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is provided. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/767,870	
			Filing Date	01/29/2004	
			First Named Inventor	Mark Puder	
			Art Unit	To be assigned	
			Examiner Name	To be assigned	
Sheet	2	of	3	Attorney Docket Number	701039-53543

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CA	ELLIS, H. ET AL., "Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study," Lancet, p. 1476, (1999).	
	CB	MENZIES, D. ET AL., "Small bowel obstruction due to postoperative adhesions: treatment patterns and associated costs in 100 hospital admissions," Ann. R. Coll. Surg. Engl., p. 40-46, (2001).	
	CC	SAED, G. M. ET AL., "Cyclooxygenase-2 is expressed in human fibroblasts isolated from intraperitoneal adhesions but not from normal peritoneal tissues," Fertil. Steril., p. 1404, (2003).	
	CD	DIZEREGA, G.S. ET AL., "Peritoneal repair and post-surgical adhesion formation," Human Reproduction Update, p. 547, (2001).	
	CE	RAY, N.F. ET AL., "Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994," J. Am. Coll. Surg., p. 1, (1998).	
	CF	CHEGINI, N., "The role of growth factors in peritoneal healing: transforming growth factor beta (TGF-beta)," Eur. J. Surg., p. 17, (1997).	
	CG	WICZYK, H.P. ET AL., "Pelvic adhesions contain sex steroid receptors and produce angiogenesis growth factors," Fertil. Steril., p. 511, (1998).	
	CH	ROUT, U.K. ET AL., "Altered expressions of VEGF mRNA splice variants during progression of uterine-peritoneal adhesions in the rat," Am. J. Reprod. Immunol., p. 299, (2000).	
	CI	MONTZ, F. ET AL., "Ability to minimize postoperative intraperitoneal adhesion formation in a murine model," Fertil. Steril., p. 1136, (1994).	
	CK	RODGERS, K. ET AL., "Reduction of adhesion formation with hyaluronic acid after peritoneal surgery in rabbits," Fertil. Steril., p. 553, (1997).	

Examiner Signature		Date Considered	9/17/07
--------------------	--	-----------------	---------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/767,870
				Filing Date	01/29/2004
				First Named Inventor	Mark Puder
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	701039-53543

CL	DIAMOND, N.P. ET AL., "A model for sidewall adhesions in the rabbit: Reduction by an absorbable barrier," Microsurg., p. 197, (1987).
CM	PANAY, N. ET AL., "New directions in the prevention of adhesion in laparoscopic surgery," Curr. Opin. Obstet. Gynecol., p. 379, (1999).
CN	SOULES, N. ET AL., "The prevention of postoperative pelvic adhesions: an animal study comparing barrier methods with dextran 70," Am. J. Obstet. Gynecol., p. 829, (1982).
CO	WISEMAN, D.M. ET AL., "The rates of adhesion development and the effects of crystalloid solution on adhesion development in pelvic surgery," Fertil. Steril., p. 702, (1998).
CP	HANEY A.F. ET AL., "A barrier composed of chemically cross-linked hyaluronic acid (Incert) reduces postoperative adhesion formation," Fertil. Steril., p. 145, (1998).
CQ	WALLWIENER, D. ET AL., "Adhesion formation of the parietal and visceral peritoneum: an explanation for the controversy on the use of autologous and alloplastic barriers?," Fertil. Steril., p. 132, (1998).
CR	RODGERS, K. ET AL., "Evaluation of polyethylene glycol/poly(lactic acid) films in the prevention of adhesions in the rabbit adhesion formation and reformation sidewall models," Fertil. Steril., p. 403, (1998).
CS	DIAMOND, M.P., "Reduction of de novo postsurgical adhesions by intraoperative pre-coating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicentre study. The Sepracoat Adhesion Study Group," Fertil. Steril., p. 1067, (1998).
CT	BOWERS, D. ET AL., "Hyaluronic acid-carboxymethylcellulose film and perianastomotic adhesions in previously irradiated rats," Am. J. Obstet. Gynecol., p. 1335-1447 (1999).
CU	Needleman, P. et al, J. Rheumatol., 24, Suppl 49:6 - 8 (1997)
CV	Samad, T. A. et al, Nature, 410(6827):471-5 (2001)

Examiner Signature		Date Considered	9/17/07
--------------------	---	-----------------	---------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.